Endocrine-Related Cancer

References

1. ↵
   1. Ansell SM,
   2. Pitot HC,
   3. Burch PA,
   4. Kvols LK,
   5. Mahoney MR &
   6. Rubin J

   2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumours. Cancer 91 1543– 1548.
2. ↵
   1. Ansell SM,
   2. Mahoney MR,
   3. Green EM &
   4. Rubin J

   2004 Topotecan in patients with advanced neuroendocrine tumours: a phase II study with significant hematologic toxicity. American Journal of Clinical Oncology 27 232– 235.
3. ↵
   1. Aparicio T,
   2. Ducreux M,
   3. Baudin E,
   4. Sabourin JC,
   5. De Baere T,
   6. Mitry E,
   7. Schlumberger M &
   8. Rougier P

   2001 Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. European Journal of Cancer 37 1014– 1019.
4. ↵
   1. Arnold R,
   2. Rinke A,
   3. Schmidt C &
   4. Hofbauer L

   2005 Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Practice & Research. Clinical Gastroenterology 19 649– 656.
5. ↵
   1. Artale S,
   2. Giannetta L,
   3. Cerea G,
   4. Pedrazzoli P,
   5. Schiavetto I,
   6. Napolitano M,
   7. Veronese S,
   8. Bramerio E,
   9. Gambacorta M,
   10. Vanzulli A
   11. et al.

   2005 Treatment of metastatic neuroendocrine carcinomas based on WHO classification. Anticancer Research 25 4463– 4469.
6. ↵
   1. Bajetta E,
   2. Rimassa L,
   3. Carnaghi C,
   4. Seregni E,
   5. Ferrari L,
   6. Di Bartolomeo M,
   7. Regalia E,
   8. Cassata A,
   9. Procopio G &
   10. Mariani L

   1998 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumours. Cancer 83 372– 378.
7. ↵
   1. Bajetta E,
   2. Catena L,
   3. Procopio G,
   4. Bichisao E,
   5. Ferrari L,
   6. Della Torre S,
   7. De Dosso S,
   8. Iacobelli S,
   9. Buzzoni R,
   10. Mariani L
   11. et al.

   2005 Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Annals of Oncology 16 1374– 1380.
8. ↵
   1. Bajetta E,
   2. Catena L,
   3. Procopio G,
   4. De Dosso S,
   5. Bichisao E,
   6. Ferrari L,
   7. Martinetti A,
   8. Platania M,
   9. Verzoni E,
   10. Formisano B
   11. et al.

   2007 Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemotherapy and Pharmacology 59 637– 642.
9. ↵
   1. Di Bartolomeo M,
   2. Bajetta E,
   3. Bochicchio AM,
   4. Carnaghi C,
   5. Somma L,
   6. Mazzaferro V,
   7. Visini M,
   8. Gebbia V,
   9. Tumolo S &
   10. Ballatore P

   1995 A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Annals of Oncology 6 77– 79.
10. ↵
    1. Bilchik AJ,
    2. Sarantou T,
    3. Foshag LJ,
    4. Giuliano AE &
    5. Ramming KP

    1997 Cryosurgical palliation of metastatic neuroendocrine tumours resistant to conventional therapy. Surgery 122 1040– 1047.
11. ↵
    1. Bukowski RM,
    2. Johnson KG,
    3. Peterson RF,
    4. Stephens RL,
    5. Rivkin SE,
    6. Neilan B &
    7. Costanzi JH

    1987 A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumours. A Southwest Oncology Group Study. Cancer 60 2891– 2895.
12. ↵
    1. Bukowski RM,
    2. Tangen C,
    3. Lee R,
    4. Macdonald JS,
    5. Einstein AB Jr.,
    6. Peterson R &
    7. Fleming TR

    1992 Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group Study. Journal of Clinical Oncology 10 1914– 1918.
13. ↵
    1. Bukowski RM,
    2. Tangen CM,
    3. Peterson RF,
    4. Taylor SA,
    5. Rinehart JJ,
    6. Eyre HJ,
    7. Rivkin SE,
    8. Fleming TR &
    9. Macdonald JS

    1994 Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 73 1505– 1508.
14. ↵
    1. Cella DF

    1995 Measuring quality of life in palliative care. Seminars in Oncology 22 73– 81.
15. ↵
    1. Chamberlain RS,
    2. Canes D,
    3. Brown KT,
    4. Saltz L,
    5. Jarnagin W,
    6. Fong Y &
    7. Blumgart LH

    2000 Hepatic neuroendocrine metastases: does intervention alter outcomes? Journal of the American College of Surgeons 190 432– 445.
16. ↵
    1. Cheng PN &
    2. Saltz LB

    1999 Failure to confirm major objective antitumour activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86 944– 948.
17. ↵
    1. Cho CS,
    2. Labow DM,
    3. Tang L,
    4. Klimstra DS,
    5. Loeffler AG,
    6. Leverson GE,
    7. Fong Y,
    8. Jarnagin WR,
    9. D'Angelica MI,
    10. Weber SM
    11. et al.

    2008 Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 113 126– 134.
18. ↵
    1. Christofori G,
    2. Naik P &
    3. Hanahan D

    1995 Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumourigenesis. Molecular Endocrinology 9 1760– 1770.
19. ↵
    1. Davies AH,
    2. Larsson G,
    3. Ardill J,
    4. Friend E,
    5. Jones L,
    6. Falconi M,
    7. Bettini R,
    8. Koller M,
    9. Sezer O,
    10. Fleissner C
    11. et al.

    2006 Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer 42 477– 484.
20. ↵
    1. Ducreux M,
    2. Ruszniewski P,
    3. Chayvialle JA,
    4. Blumberg J,
    5. Cloarec D,
    6. Michel H,
    7. Raymond JM,
    8. Dupas JL,
    9. Gouerou H,
    10. Jian R
    11. et al.

    2000 The antitumoural effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumours. American Journal of Gastroenterology 95 3276– 3281.
21. ↵
    1. Ekeblad S,
    2. Sundin A,
    3. Janson ET,
    4. Welin S,
    5. Granberg D,
    6. Kindmark H,
    7. Dunder K,
    8. Kozlovacki G,
    9. Orlefors H,
    10. Sigurd M
    11. et al.

    2007 Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumours. Clinical Cancer Research 13 2986– 2991.
22. ↵
    1. Engstrom PF,
    2. Lavin PT,
    3. Moertel CG,
    4. Folsch E &
    5. Douglass HO Jr.

    1984 Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumour. Journal of Clinical Oncology 2 1255– 1259.
23. ↵
    1. Ezziddin S,
    2. Logvinski T,
    3. Yong-Hing C,
    4. Ahmadzadehfar H,
    5. Fischer HP,
    6. Palmedo H,
    7. Bucerius J,
    8. Reinhardt MJ &
    9. Biersack HJ

    2006 Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumours. Journal of Nuclear Medicine 47 223– 233.
24. ↵
    1. Faiss S,
    2. Scherubl H,
    3. Riecken EO &
    4. Wiedenmann B

    1996 Drug therapy in metastatic neuroendocrine tumours of the gastroenteropancreatic system. Recent Results in Cancer Research 142 193– 207.
25. ↵
    1. Faiss S,
    2. Pape UF,
    3. Bohmig M,
    4. Dorffel Y,
    5. Mansmann U,
    6. Golder W,
    7. Riecken EO &
    8. Wiedenmann B

    2003 Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumours – the International Lanreotide and Interferon Alfa Study Group. Journal of Clinical Oncology 21 2689– 2696.
26. ↵
    1. Filosso PL,
    2. Croce S,
    3. Oliaro A &
    4. Ruffini E

    2000 Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung. Journal of Cardiovascular Surgery 41 773– 776.
27. ↵
    Fine RL, Fogelman DR & Schreibman S 2005 Effective treatment of neuroendocrine tumours with temozolomide and capecitabine. Journal of Clinical Oncology 23 (Suppl 16S) abstract 4216.
28. ↵
    1. Fjallskog ML,
    2. Granberg DP,
    3. Welin SL,
    4. Eriksson C,
    5. Oberg KE,
    6. Janson ET &
    7. Eriksson BK

    2001 Treatment with cisplatin and etoposide in patients with neuroendocrine tumours. Cancer 92 1101– 1107.
29. ↵
    1. Furukawa M,
    2. Raffeld M,
    3. Mateo C,
    4. Sakamato A,
    5. Moody T,
    6. Ito T,
    7. Venzon D,
    8. Serrano J &
    9. Jensen R

    2005 Increased expression of insulin-like growth factor 1 and/or its receptor in gastrinomas is associated with low curability, increased growth, and development of metastases. Clinical Cancer Research 11 3233– 3242.
30. ↵
    1. Gates J,
    2. Hartnell GG,
    3. Stuart KE &
    4. Clouse ME

    1999 Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 19 399– 414.
31. ↵
    1. Gonzalez MA,
    2. Biswas S,
    3. Clifton L &
    4. Corrie PG

    2003 Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. British Journal of Cancer 89 455– 456.
32. ↵
    1. Grama D,
    2. Eriksson B,
    3. Martensson H,
    4. Cedermark B,
    5. Ahren B,
    6. Kristoffersson A,
    7. Rastad J,
    8. Oberg K &
    9. Akerstrom G

    1992 Clinical characteristics, treatment and survival in patients with pancreatic tumours causing hormonal syndromes. World Journal of Surgery 16 632– 639.
33. ↵
    1. Gupta S,
    2. Yao JC,
    3. Ahrar K,
    4. Wallace MJ,
    5. Morello FA,
    6. Madoff DC,
    7. Murthy R,
    8. Hicks ME &
    9. Ajani JA

    2003 Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumours: the M.D. Anderson experience. Cancer Journal 9 261– 267.
34. ↵
    1. Hainsworth JD,
    2. Spigel DR,
    3. Litchy S &
    4. Greco FA

    2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. Journal of Clinical Oncology 24 3548– 3554.
35. ↵
    1. Hatton MQ &
    2. Reed NS

    1997 Chemotherapy for neuroendocrine tumours: the Beatson Oncology Centre experience. Clinical Oncology 9 385– 389.
36. ↵
    Heitz PU, Komminoth P, Perren A, Klimstra DS, Dayal Y, Bordi C, Lechago J, Centeno BA & Klöppel G 2004 Tumours of the endocrine pancreas. In World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Endocrine Organs, pp 175–208. Eds RA DeLellis, RV Lloyd, PU Heitz & C Eng. Lyons, France: IARC Press.
37. ↵
    1. Hobday T,
    2. Rubin J &
    3. Holen K

    2007 MCO44h, a phase II trial of sorafenib in patients with metastatic neuroendocrine tumours (NET): a phase II consortium (P2C) study. Journal of Clinical Oncology 25 (Suppl 18S) abstract 4504.
38. ↵
    1. Imam H,
    2. Eriksson B,
    3. Lukinius A,
    4. Janson ET,
    5. Lindgren PG,
    6. Wilander E &
    7. Oberg K

    1997 Induction of apoptosis in neuroendocrine tumours of the digestive system during treatment with somatostatin analogs. Acta Oncologica 36 607– 614.
39. ↵
    1. Jacobsen M &
    2. Hanssen L

    1995 Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. Journal of Internal Medicine 237 269– 275.
40. ↵
    1. De Jong M,
    2. Breeman WA,
    3. Bernard HF,
    4. Kooij PP,
    5. Slooter GD,
    6. Van Eijck CH,
    7. Kwekkeboom DJ,
    8. Valkema R,
    9. Macke HR &
    10. Krenning EP

    1999 Therapy of neuroendocrine tumours with radiolabeled somatostatin-analogues. Quarterly Journal of Nuclear Medicine 43 356– 366.
41. ↵
    1. Kaltsas G,
    2. Korbonits M,
    3. Heintz E,
    4. Mukherjee JJ,
    5. Jenkins PJ,
    6. Chew SL,
    7. Reznek R,
    8. Monson JP,
    9. Besser GM,
    10. Foley R
    11. et al.

    2001a Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumours. Journal of Clinical Endocrinology and Metabolism 86 895– 902.
42. ↵
    1. Kaltsas G,
    2. Mukherjee JJ,
    3. Plowman PN &
    4. Grossman AB

    2001b The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours. Clinical Endocrinology 55 575– 587.
43. ↵
    1. Kerr C

    2006 Oral regimen for metastatic neuroendocrine tumours. Lancet Oncology 7 197.
44. ↵
    1. Klöppel G,
    2. Perren A &
    3. Heitz PU

    2004 The gastroenteropancreatic neuroendocrine cell system and its tumours: the WHO classification. Annals of the New York Academy of Sciences 1014 13– 27.
45. ↵
    1. Kouvaraki MA,
    2. Ajani JA,
    3. Hoff P,
    4. Wolff R,
    5. Evans DB,
    6. Lozano R &
    7. Yao JC

    2004 Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. Journal of Clinical Oncology 22 4762– 4771.
46. ↵
    1. Kress O,
    2. Wagner HJ,
    3. Wied M,
    4. Klose KJ,
    5. Arnold R &
    6. Alfke H

    2003 Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumours – a retrospective single-center analysis. Digestion 68 94– 101.
47. ↵
    1. Krzyzanowska MK,
    2. Tsao MS,
    3. Oza AM,
    4. Haider M,
    5. Feld R,
    6. Knox J,
    7. Chin S,
    8. Hu H &
    9. Siu LL

    2006 Capecitabine plus rofecoxib show no activity in patients with metastatic neuroendocrine tumours. Clinical Oncology 18 88– 89.
48. ↵
    1. Kulke MH,
    2. Kim H,
    3. Clark JW,
    4. Enzinger PC,
    5. Lynch TJ,
    6. Morgan JA,
    7. Vincitore M,
    8. Michelini A &
    9. Fuchs CS

    2004a A phase II trial of gemcitabine for metastatic neuroendocrine tumours. Cancer 101 934– 939.
49. ↵
    1. Kulke MH,
    2. Kim H,
    3. Stuart K,
    4. Clark JW,
    5. Ryan DP,
    6. Vincitore M,
    7. Mayer RJ &
    8. Fuchs CS

    2004b A phase II study of docetaxel in patients with metastatic carcinoid tumours. Cancer Investigation 22 353– 359.
50. ↵
    1. Kulke MH,
    2. Stuart K,
    3. Enzinger PC,
    4. Ryan DP,
    5. Clark JW,
    6. Muzikansky A,
    7. Vincitore M,
    8. Michelini A &
    9. Fuchs CS

    2006a Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumours. Journal of Clinical Oncology 24 401– 406.
51. ↵
    1. Kulke MH,
    2. Wu B,
    3. Ryan DP,
    4. Enzinger PC,
    5. Zhu AX,
    6. Clark JW,
    7. Earle CC,
    8. Michelini A &
    9. Fuchs CS

    2006b A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumours. Digestive Diseases and Sciences 51 1033– 1038.
52. ↵
    1. Kulke MH,
    2. Lenz HJ,
    3. Meropol NJ,
    4. Posey J,
    5. Ryan DP,
    6. Picus J,
    7. Bergsland E,
    8. Stuart K,
    9. Tye L,
    10. Huang X
    11. et al.

    2008 Activity of sunitinib in patients with advanced neuroendocrine tumours. Journal of Clinical Oncology 26 3403– 3410.
53. ↵
    1. Kwekkeboom DJ,
    2. de Herder WW,
    3. Kam BL,
    4. van Eijck CH,
    5. van Essen M,
    6. Kooij PP,
    7. Feelders RA,
    8. van Aken MO &
    9. Krenning EP

    2008 Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124– 2130.
54. ↵
    1. Lankat-Buttgereit B,
    2. Horsch D,
    3. Barth P,
    4. Arnold R,
    5. Blocker S &
    6. Goke R

    2005 Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumour cell growth. Digestion 71 131– 140.
55. ↵
    1. de Lima Lopes G Jr.,
    2. Chiappori A,
    3. Simon G,
    4. Haura E,
    5. Sullivan D,
    6. Antonia S,
    7. Langevin M,
    8. Lush R &
    9. Rocha-Lima CM

    2007 Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumours: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer 109 1413– 1419.
56. ↵
    1. McCollum AD,
    2. Kulke MH,
    3. Ryan DP,
    4. Clark JW,
    5. Shulman LN,
    6. Mayer RJ,
    7. Bartel S &
    8. Fuchs CS

    2004 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumours. American Journal of Clinical Oncology 27 485– 488.
57. ↵
    1. Mitry E,
    2. Baudin E,
    3. Ducreux M,
    4. Sabourin JC,
    5. Rufie P,
    6. Aparicio T,
    7. Aparicio T,
    8. Lasser P,
    9. Elias D,
    10. Duvillard P
    11. et al.

    1999 Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. British Journal of Cancer 81 1351– 1355.
58. ↵
    1. Modlin IM,
    2. Lye KD &
    3. Kidd M

    2003 A 5-decade analysis of 13,715 carcinoid tumours. Cancer 97 934– 959.
59. ↵
    1. Moertel CG &
    2. Hanley JA

    1979 Combination chemotherapy trials in metastatic carcinoid tumour and the malignant carcinoid syndrome. Cancer Clinical Trials 2 327– 334.
60. ↵
    1. Moertel CG,
    2. Hanley JA &
    3. Johnson LA

    1980 Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 303 1189– 1194.
61. ↵
    1. Moertel CG,
    2. Kvols LK,
    3. O'Connell MJ &
    4. Rubin J

    1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68 227– 232.
62. ↵
    1. Moertel CG,
    2. Lefkopoulo M,
    3. Lipsitz S,
    4. Hahn RG &
    5. Klaassen D

    1992 Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. New England Journal of Medicine 326 519– 523.
63. ↵
    1. Moertel CG,
    2. Johnson CM,
    3. McKusick MA,
    4. Martin JK Jr.,
    5. Nagorney DM,
    6. Kvols LK,
    7. Rubin J &
    8. Kunselman S

    1994 The management of patients with advanced carcinoid tumours and islet cell carcinomas. Annals of Internal Medicine 120 302– 309.
64. ↵
    1. Motzer RJ,
    2. Michaelson MD,
    3. Rosenberg J,
    4. Bukowski RM,
    5. Curti BD,
    6. George DJ,
    7. Hudes GR,
    8. Redman BG,
    9. Margolin KA &
    10. Wilding G

    2007 Sunitinib efficacy against advanced renal cell carcinoma. Journal of Urology 178 1883– 1887.
65. ↵
    1. Mukherjee JJ,
    2. Kaltsas GA,
    3. Islam N,
    4. Plowman PN,
    5. Foley R,
    6. Hikmat J,
    7. Britton KE,
    8. Jenkins PJ,
    9. Chew SL,
    10. Monson JP
    11. et al.

    2001 Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clinical Endocrinology 55 47– 60.
66. ↵
    1. Murray-Lyon IM,
    2. Eddleston AL,
    3. Williams R,
    4. Brown M,
    5. Hogbin BM,
    6. Bennett A,
    7. Edwards JC &
    8. Taylor KW

    1968 Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 2 895– 898.
67. ↵
    1. Musunuru S,
    2. Chen H,
    3. Rajpal S,
    4. Stephani N,
    5. McDermott JC,
    6. Holen K,
    7. Rikkers LF &
    8. Weber SM

    2006 Metastatic neuroendocrine hepatic tumours: resection improves survival. Archives of Surgery 141 1000– 1004.
68. ↵
    1. Nave H,
    2. Mossinger E,
    3. Feist H,
    4. Lang H &
    5. Raab H

    2001 Surgery as primary treatment in patients with liver metastases from carcinoid tumours: a retrospective, unicentric study over 13 years. Surgery 129 170– 175.
69. ↵
    1. Neuberger J

    1999 Liver transplantation. Quarterly Journal of Medicine 92 547– 550.
70. ↵
    1. Obendorfer S

    1907 KarzinoideTumouren des Dunndarms. Frankfurter Zeitschrift für Pathologie 1 425– 429.
71. ↵
    1. Oberg K

    1993 Chemotherapy and biotherapy in neuroendocrine tumours. Current Opinion in Oncology 5 110– 120.
72. ↵
    1. Oberg K

    1998 Carcinoid tumours: current concepts in diagnosis and treatment. Oncologist 3 339– 345.
73. ↵
    1. Oberg K

    Neuroendocrine gastrointestinal tumours – a condensed overview of diagnosis and treatment Annals of Oncology 10 Suppl 2 1999 S3– S8.
74. ↵
    1. Oberg K

    Chemotherapy and biotherapy in the treatment of neuroendocrine tumours Annals of Oncology 12 Suppl 2 2001 S111– S114.
75. ↵
    1. Oberg K,
    2. Funa K &
    3. Alm G

    1983 Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumours and carcinoid syndrome. New England Journal of Medicine 309 129– 133.
76. ↵
    1. Oberg K,
    2. Eriksson B &
    3. Janson ET

    Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumours Digestion 55 Suppl 3 1994 64– 69.
77. ↵
    1. O'Donnell PH &
    2. Ratain MJ

    2007 Evaluating the activity of temsirolimus in neuroendocrine cancer. British Journal of Cancer 177 178– 179.
78. ↵
    1. Ollivier S,
    2. Fonck M,
    3. Becouarn Y &
    4. Brunet R

    1998 Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumours: a phase II trial. American Journal of Clinical Oncology 21 237– 240.
79. ↵
    O'Toole D & Ruszniewski P 2006 Medical management of gastroenteropancreatic endocrine tumours: antiproliferative treatment. In Handbook of Neuroendocrine Tumours: Their current and future management, pp 135–156. Eds M Caplin & L Kvols. Bristol, UK: BioScientifica Ltd.
80. ↵
    1. Panzuto F,
    2. Nasoni S,
    3. Falconi M,
    4. Corleto VD,
    5. Capurso G,
    6. Cassetta S,
    7. Di Fonzo M,
    8. Tornatore V,
    9. Milione M,
    10. Angeletti S
    11. et al.

    2005 Prognostic factors and survival in endocrine tumour patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer 12 1083– 1092.
81. ↵
    1. Pape UF,
    2. Jann H,
    3. Müller-Nordhorn J,
    4. Bockelbrink A,
    5. Berndt U,
    6. Willich SN,
    7. Koch M,
    8. Röcken C,
    9. Rindi G &
    10. Wiedenmann B

    2008 Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumours. Cancer 113 256– 265.
82. ↵
    1. Que FG,
    2. Nagorney DM,
    3. Batts KP,
    4. Linz LJ &
    5. Kvols LK

    1995 Hepatic resection for metastatic neuroendocrine carcinomas. American Journal of Surgery 169 36– 42.
83. ↵
    1. Ramage JK,
    2. Davies AH,
    3. Ardill J,
    4. Bax N,
    5. Caplin M,
    6. Grossman A,
    7. Hawkins R,
    8. McNicol AM,
    9. Reed N,
    10. Sutton R
    11. et al.

    Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours Gut 54 Suppl 4 2005 iv1– iv16.
84. ↵
    1. Ramanathan RK,
    2. Cnaan A,
    3. Hahn RG,
    4. Carbone PP &
    5. Haller DG

    2001 Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Annals of Oncology 12 1139– 1143.
85. ↵
    Raymond E, Raoul J-L, Niccoli P, Bang Y-J, Borbath I, Lombard-Bohas C, Metrakos P, Lu D-R, Blanckmeister C & Vinik A 2009 Phase III randomised double-blind trial of sunitinib versus placebo in patients with progressive, well-differentiated malignant pancreatic islet cell tumours. Annals of Oncology 20 (10) (Suppl) abstract O-008.
86. ↵
    1. Rindi G,
    2. Kloppel G,
    3. Alhman H,
    4. Caplin M,
    5. Couvelard A,
    6. de Herder WW,
    7. Eriksson B,
    8. Falchetti A,
    9. Falconi M,
    10. Komminoth P
    11. et al.

    2006 TNM staging of foregut (neuro)endocrine tumours: a consensus proposal including a grading system. Virchows Archiv 449 395– 401.
87. ↵
    1. Rindi G,
    2. Kloppel G,
    3. Couvelard A,
    4. Komminoth P,
    5. Korner M,
    6. Lopes JM,
    7. McNichol AM,
    8. Nilsson O,
    9. Perren A,
    10. Scoazec JY
    11. et al.

    2007 TNM staging of midgut and hindgut (neuro) endocrine tumours: a consensus proposal including a grading system. Virchows Archiv 451 757– 762.
88. ↵
    1. Rinke A,
    2. Muller H,
    3. Schade-Brittinger C,
    4. Klose K,
    5. Barth P,
    6. Wied M,
    7. Mayer C,
    8. Aminossadati B,
    9. Pape U,
    10. Blaker M
    11. et al.

    2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octtreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: a report from the PROMID Study Group. Journal of Clinical Oncology 28 4656– 4663.
89. ↵
    1. Rivera E &
    2. Ajani JA

    1998 Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. American Journal of Clinical Oncology 21 36– 38.
90. ↵
    1. La Rosa S,
    2. Uccella S,
    3. Finzi G,
    4. Albarello L,
    5. Sessa F &
    6. Capella C

    2003 Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumours: correlation with microvessel density and clinicopathologic features. Human Pathology 34 18– 27.
91. ↵
    1. Rougier P,
    2. Oliveira J,
    3. Ducreux M,
    4. Theodore C,
    5. Kac J &
    6. Droz JP

    1991 Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin. European Journal of Cancer 27 1380– 1382.
92. ↵
    1. Ruutiainen AT,
    2. Soulen MC,
    3. Tuite CM,
    4. Clark TW,
    5. Mondschein JI,
    6. Stavropoulos SW &
    7. Trerotola SO

    2007 Chemoembolization and bland embolization of neuroendocrine tumour metastases to the liver. Journal of Vascular and Interventional Radiology 18 847– 855.
93. ↵
    Sarkar D, Williams M, Hochhauser D, Caplin M, Bouvier C, Buscombe J, Tibbals J & Meyer T 2004 5-Fluorouracil, cisplatin and streptozocin (FCiSt): an effective new regimen for advanced pancreatic neuroendocrine tumours. ASCO Gastrointestinal Cancers Symposium. abstract 100.
94. ↵
    1. Sarmiento JM,
    2. Heywood G,
    3. Rubin J,
    4. Ilstrup DM,
    5. Nagorney DM &
    6. Que FG

    2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 197 29– 37.
95. ↵
    1. Shebani KO,
    2. Souba WW,
    3. Finkelstein DM,
    4. Stark PC,
    5. Elgadi KM,
    6. Tanabe KK &
    7. Ott MJ

    1999 Prognosis and survival in patients with gastrointestinal tract carcinoid tumours. Annals of Surgery 229 815– 821.
96. ↵
    Solcia E, Klöppel G & Sobin LH 2000 Histological typing of endocrine tumours. In World Health Organisation International Histological Classification of Endocrine Tumours, edn 2, pp 56–58. New York, USA: Springer.
97. ↵
    1. Strosberg JR,
    2. Choi J,
    3. Gardner N &
    4. Kvols L

    2008 First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolamide. Journal of Clinical Oncology 26 (Suppl 15S) abstract 4612.
98. ↵
    1. Sun W,
    2. Lipsitz S,
    3. Catalano P,
    4. Mailliard JA &
    5. Haller DG

    2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumours: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897– 4904.
99. ↵
    1. Terris B,
    2. Scoazec JY,
    3. Rubbia L,
    4. Bregeaud L,
    5. Pepper MS,
    6. Ruszniewski P,
    7. Belghiti J,
    8. Flejou J &
    9. Degott C

    1998 Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 32 133– 138.
100. ↵
     1. Therasse P,
     2. Arbuck SG,
     3. Eisenhauer EA,
     4. Wanders J,
     5. Kaplan RS,
     6. Rubinstein L,
     7. Verweij J,
     8. Van Glabbeke M,
     9. van Oosterom AT,
     10. Christian MC
     11. et al.

     2000 New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute 92 205– 216.
101. ↵
     1. Van Cutsem E,
     2. Twelves C,
     3. Cassidy J,
     4. Allman D,
     5. Bajetta E,
     6. Boyer M,
     7. Bugat R,
     8. Findlay M,
     9. Frings S,
     10. Jahn M
     11. et al.

     2001 Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Journal of Clinical Oncology 19 4097– 4106.
102. ↵
     1. Vilar E,
     2. Salazar R,
     3. Perez-Garcia J,
     4. Cortes J,
     5. Oberg K &
     6. Tabernero J

     2007 Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumours. Endocrine-Related Cancer 14 221– 232.
103. ↵
     1. Virgolini I,
     2. Traub T,
     3. Novotny C,
     4. Leimer M,
     5. Fuger B,
     6. Li SR,
     7. Patri P,
     8. Pangerl T,
     9. Angelberger P,
     10. Raderer M
     11. et al.

     2002 Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Current Pharmaceutical Design 8 1781– 1807.
104. ↵
     1. Wang DG

     1999 Apoptosis in neuroendocrine tumours. Clinical Endocrinology 51 1– 9.
105. ↵
     1. Yao JC

     2007 Neuroendocrine tumours. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Practice & Research. Clinical Endocrinology & Metabolism 21 163– 172.
106. ↵
     1. Yao J,
     2. Phan A,
     3. Chang D,
     4. Wolff R,
     5. Hess K,
     6. Gupta S,
     7. Jacobs C,
     8. Mares J,
     9. Landgraf A,
     10. Rashid A
     11. et al.

     2008a Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumours: results of a phase II study. Journal of Clinical Oncology 26 4311– 4318.
107. ↵
     1. Yao JC,
     2. Hassan M,
     3. Phan A,
     4. Dagohoy C,
     5. Leary C,
     6. Mares JE,
     7. Abdalla EK,
     8. Fleming JB,
     9. Vauthey JN,
     10. Rashid A
     11. et al.

     2008b One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063– 3072.
108. ↵
     1. Yao JC,
     2. Phan A,
     3. Hoff PM,
     4. Chen HX,
     5. Charnsangavej C,
     6. Yeung SC,
     7. Hess K,
     8. Ng C,
     9. Abbruzzese JL &
     10. Ajani JA

     2008c Targeting vascular endothelial growth factor in advanced carcinoid tumour: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology 26 1316– 1323.
109. ↵
     Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St. Peter J, Haas T, Lebwohl D et al. 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 28 69–76.
110. ↵
     1. Zitzmann K,
     2. De Toni EN,
     3. Brand S,
     4. Goke B,
     5. Meinecke J,
     6. Spottl G,
     7. Meyer HH &
     8. Auernhammer CJ

     2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumour cells. Neuroendocrinology 85 54– 60.